For instance, co-treatment with NF-κB inhibitors, like SN50 or bortezomib, may suppress chemotherapy-induced NF-κB activation, thereby increasing cancer cell susceptibility to chemotherapeutic agents [105]. The gene discussed is NFKB1; the disease is cancer.